

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
VIRTUAL PLATFORM**

January 20, 2021

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for October 28, 2020 meeting
- IV. Review of draft meeting summary for October 28, 2020 meeting
- V. Secretary's report
- VI. Old Business
 - A. United Healthcare clinical criteria not met denials report
 - B. Addendum to opioid protocol
- VII. New Business
 - A. Proposed protocol for Daraprim[®] (pyrimethamine)
 - B. Proposed protocol for Increlex[®] (mecasermin)
 - C. Proposed protocol for dose limit on Victoza[®] (liraglutide)
- VIII. A. Informational Highlights/Reports
 1. DXC Technology/NJ HMO 3rd Quarter 2020 Prior Authorization Report
 2. Summary of DURB Action Items
 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
(b) Physician-administered/Antiviral drugs by amount paid

B. Medication information:

 1. COVID-19 Vaccines information
<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>
 2. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html>
 3. New Jersey COVID-19 Information Hub
<https://covid19.nj.gov/>
- IX. Referenced Materials:
 1. Opioid protocol (approved October 2018)
 2. Update to Vimizim approved protocol – change of criterion #3
 3. Update to Naglazyme approved protocol – change of criterion #3
 4. Update to Mepsevii approved protocol – change of criterion #3